Who is sponsoring NCT04052243?

NCT04052243 is sponsored by Aarhus University Hospital.

What drugs are being tested in NCT04052243?

Interventions in NCT04052243: Invasive exercise testing.

What condition does NCT04052243 study?

NCT04052243 studies Chronic Thromboembolic Pulmonary Hypertension.

Is NCT04052243 still recruiting?

NCT04052243 is currently status unknown. Last updated 20 July 2022.

Last reviewed 2022-07-20 · How we verify

NCT04052243: EXPERT-BPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemodynamic Effects of BPA at Rest and During Exercise in CTEPH

Status unknown NA Last updated 20 July 2022

What this trial tests

NA trial testing Invasive exercise testing in Chronic Thromboembolic Pulmonary Hypertension in 80 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
31 December 2023

30 June 2024

Quick facts

Lead sponsor	Aarhus University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	80
Start date	1 January 2021
Primary completion	31 December 2023
Estimated completion	30 June 2024
Sites	3 locations across Denmark, Japan, Poland

Drugs / interventions tested

Invasive exercise testing

Conditions studied

Chronic Thromboembolic Pulmonary Hypertension — all drugs for Chronic Thromboembolic Pulmonary Hypertension →

Sponsor

Aarhus University Hospital

Who can join

18 and older, any sex, with Chronic Thromboembolic Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by obstruction of the pulmonary vasculature by residual organized thrombi, leading to increased pulmonary vascular resistance (PVR), progressive pulmonary hypertension, and right heart failure. Medical therapy and balloon angioplasty (BPA) are effective treatment alternatives in lowering pulmonary pressures and increasing pulmonary flow. The aim of this study is to assess the hemodynamic effects of BPA or medical therapy on the pressure-flow relationship in the pulmonary vasculature and the pulmonary vascular compliance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: State of the art.
Jin Q, Zhao ZH, Luo Q, Zhao Q, et al · · 2020 · cited 21× · PMID 32742980 · DOI 10.12998/wjcc.v8.i13.2679
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results.
McInnis MC, Chow CT, Boutet A, Mafeld S, et al · · 2021 · PMID 34820116 · DOI 10.1177/20458940211059994

Verify or expand the search:

Other recruiting trials for Chronic Thromboembolic Pulmonary Hypertension

Currently open trials in the same condition.

NCT07272798 — Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension · recruiting
NCT07254078 — Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension · recruiting
NCT06922240 — Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART) · Phase 3 · recruiting
NCT06081881 — Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism · recruiting
NCT06715280 — Switching of Sildenafil to Riociguat in CTEPH Patients · Phase 4 · recruiting

Other Aarhus University Hospital trials

Trials by the same sponsor.

NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04052243 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
Last refreshed: 20 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04052243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing